Table 2.

Baseline characteristics of subjects by menopause status

	Premenopausal		Perimenopausal		Postmenopausal
	n	Value	n	Value	n	Value
Characteristic, mean (minimum, maximum)
Age, yearsa	99	35 (15, 44)	71	49 (44, 55)	147	67 (56, 86)
Weight	99	70 (41, 128)	71	76 (40, 125)	147	74 (41, 129)
Baseline 6MWDa	99	371 (210, 450)	70	367 (180, 450)	147	318 (150, 463)
PAH etiologyb
Idiopathic/familial	50	50.5	47	66.2	82	55.8
Anorexigen use	4	4	5	7	5	3.4
Connective tissue disease	20	20.2	15	21.1	51	34.7
Associated with an atrial septal defect	21	21.2	4	5.6	5	3.4
Surgical repair of VSD or PDA ≥1 year	4	4	0	0	4	2.7
Concomitant use of bosentan	60	60.6	41	57.7	74	50.3
Treatment
Placebo	22	22.2	13	18.3	30	20.4
Tadalafil 2.5 mg	19	19.2	8	11.3	37	25.2
Tadalafil 10 mg	16	16.2	21	29.6	30	20.4
Tadalafil 20 mg	19	19.2	16	22.5	27	18.4
Tadalafil 40 mg	23	23.2	13	18.3	23	15.6

^NoteExcept where otherwise noted, data are no. (%) of patients. 6MWD: 6-minute walk distance; PAH: pulmonary arterial hypertension; VSD: ventricular septal defect; PDA: patent ductus arteriosus.

^aP < 0.0001.

^bP = 0.0001.